Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Mauro Ferrari Sells 7,530 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Mauro Ferrari sold 7,530 shares of the stock in a transaction on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the sale, the director owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. This trade represents a 9.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mauro Ferrari also recently made the following trade(s):

• On Friday, November 28th, Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $56.39, for a total value of $493,412.50.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $67.25 on Wednesday. The firm has a 50 day moving average of $52.96 and a 200-day moving average of $33.93. The company has a market cap of $9.14 billion, a price-to-earnings ratio of -840.52 and a beta of 1.28. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $72.36.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. Virtus Advisers LLC bought a new position in Arrowhead Pharmaceuticals in the second quarter worth about $34,000. Salomon & Ludwin LLC bought a new position in Arrowhead Pharmaceuticals in the third quarter worth about $34,000. Nisa Investment Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,308 shares during the period. Finally, Federated Hermes Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $52,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 20th. Piper Sandler upped their price objective on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Royal Bank Of Canada lifted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, December 1st. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.89.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.